Showing 1 - 10 of 895
in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both … AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on …
Persistent link: https://www.econbiz.de/10013474156
Persistent link: https://www.econbiz.de/10003329482
Purpose This paper aims to review the latest management developments across the globe and pinpoint practical implications from cutting-edge research and case studies. Design/methodology/approach This briefing is prepared by an independent writer who adds their own impartial comments and places...
Persistent link: https://www.econbiz.de/10015012234
Persistent link: https://www.econbiz.de/10009317178
Persistent link: https://www.econbiz.de/10011427811
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Patent-based measures are frequently used as indicators in empirical research on innovation and technology as well as on firms' strategies and organizational choices to characterize inventions or, more generally, innovative activities and the technological capabilities of organizations. A clear...
Persistent link: https://www.econbiz.de/10010258420
Persistent link: https://www.econbiz.de/10011539625
Patent-based measures are frequently used as indicators in empirical research on innovation and technological change. Currently, there is little evidence as to what extent patent-based indicators relate to product market outcomes. Using a unique dataset that links outcomes from product...
Persistent link: https://www.econbiz.de/10010497622